(Q52767165)

7 May 2018

review article

1 reference

title

[Raynaud phenomenon in dermatology : Part 2: therapy]. (English)

1 reference

7 May 2018

author

Cord Sunderkötter

series ordinal

1

1 reference

7 May 2018

Gabriela Riemekasten

series ordinal

2

object named as

G Riemekasten

1 reference

7 May 2018

language of work or name

German

0 references

publication date

1 October 2006

1 reference

7 May 2018

published in

Die Dermatologie

1 reference

7 May 2018

volume

57

1 reference

7 May 2018

issue

10

1 reference

7 May 2018

page(s)

927-38; quiz 941

1 reference

7 May 2018

https://scigraph.springernature.com/pub.10.1007/s00105-006-1218-4

exact match

0 references

cites work

Regression of renal vascular fibrosis by endothelin receptor antagonism

1 reference

https://api.crossref.org/works/10.1007%2FS00105-006-1218-4

Subjective and objective assessment of enalapril in primary Raynaud's phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00105-006-1218-4

Effects of beta-adrenoreceptor-blocking drugs in patients with Raynaud's phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00105-006-1218-4

Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00105-006-1218-4

Statins: novel additions to the dermatologic arsenal?

21 January 2018

1 reference

12 December 2020

Enalapril in Raynaud's phenomenon

1 reference

12 December 2020

Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial

1 reference

12 December 2020

Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years

1 reference

12 December 2020

[The effect of beraprost sodium on the Raynaud's phenomenon]

1 reference

12 December 2020

The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon

1 reference

12 December 2020

Sildenafil citrate therapy for pulmonary arterial hypertension

1 reference

12 December 2020

Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial

1 reference

12 December 2020

[Comparative study of misoprostol and nifedipine in the treatment of Raynaud's phenomenon secondary to systemic diseases. Hemodynamic assessment with Doppler duplex]

1 reference

12 December 2020

Improvement in digital flexibility and dexterity following ingestion of sildenafil citrate (viagra) in limited systemic sclerosis

1 reference

12 December 2020

Prolonged improvement of Raynaud's phenomenon and scleroderma after recombinant tissue plasminogen activator therapy

1 reference

12 December 2020

Iloprost therapy in systemic sclerosis

1 reference

12 December 2020

Increased endothelin-1 and its localization during the development of bleomycin-induced pulmonary fibrosis in rats

1 reference

12 December 2020

A double-blind controlled trial of low dose acetylsalicylic acid and dipyridamole in the treatment of Raynaud's phenomenon

1 reference

12 December 2020

Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study

1 reference

12 December 2020

[Iloprost administration over 21 days as an effective therapy in systemic scleroderma--case report and review of the literature]

1 reference

12 December 2020

Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis

1 reference

12 December 2020

Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis

1 reference

12 December 2020

Frequency and analysis of factors closely associated with the development of depressive symptoms in patients with scleroderma.

1 reference

12 December 2020

Assessment of vascular function in systemic sclerosis: Indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production

1 reference

12 December 2020

Effects of short-term treatment with vitamin E in systemic sclerosis: a double blind, randomized, controlled clinical trial of efficacy based on urinary isoprostane measurement

1 reference

12 December 2020

Diltiazem induces remission of calcinosis in scleroderma

1 reference

12 December 2020

Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine

1 reference

12 December 2020

Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma

1 reference

12 December 2020

Treatment of Raynaud's phenomenon with captopril

1 reference

12 December 2020

Diltiazem therapy for symptoms associated with nutcracker esophagus.

1 reference

12 December 2020

Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients

1 reference

12 December 2020

Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon

1 reference

12 December 2020

Flunarizine is effective in prophylaxis of headache associated with scleroderma

1 reference

12 December 2020

Successful treatment of Raynaud's phenomenon with pentoxifylline

1 reference

12 December 2020

Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis

1 reference

12 December 2020

Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy

1 reference

12 December 2020

Vasoactive therapies in systemic sclerosis.

1 reference

12 December 2020

Functional vascular disorders: treatment with pentoxifylline

1 reference

12 December 2020

A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon

1 reference

12 December 2020

Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicenter Group for the Study of Vascular Acrosyndromes

1 reference

12 December 2020

Prazosin for Raynaud's phenomenon in progressive systemic sclerosis

1 reference

12 December 2020

Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis

1 reference

12 December 2020

Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis

1 reference

12 December 2020

Evaluation of depression and anxiety in patients with systemic sclerosis

1 reference

12 December 2020

Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis

1 reference

12 December 2020

[Effect of diltiazem on cold-induced left ventricular dysfunction in patients with systemic sclerosis]

1 reference

12 December 2020

Recommendations of the German Society of Rheumatology on therapy of Raynaud syndrome and acral ulcerations

1 reference

12 December 2020

[Efficacy of beraprost sodium on Raynaud's phenomenon in patients with systemic sclerosis]

1 reference

12 December 2020

Rational use of calcium-channel antagonists in Raynaud's phenomenon

1 reference

12 December 2020

Iloprost as cyclic five-day infusions in the treatment of scleroderma. An open pilot study in 20 patients treated for one year

1 reference

12 December 2020

Vascular effects of pentoxifylline in humans.

1 reference

12 December 2020

The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial.

1 reference

12 December 2020

Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study

1 reference

12 December 2020

Systemic sclerosis. A vascular perspective

1 reference

12 December 2020

Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study

1 reference

12 December 2020

A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome

1 reference

12 December 2020

The clinical effect of felodipine and nifedipine in Raynaud's phenomenon

1 reference

12 December 2020

Bosentan therapy for pulmonary arterial hypertension

1 reference

12 December 2020

Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon.

1 reference

12 December 2020

Effects of five-day versus one-day infusion of iloprost on the peripheral microcirculation in patients with systemic sclerosis

1 reference

12 December 2020

Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study

1 reference

12 December 2020

Trial of platelet-inhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin

1 reference

12 December 2020

A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon

1 reference

12 December 2020

10.1007/S00105-006-1218-4

Identifiers

DOI

1 reference

7 May 2018

1 reference

7 May 2018